PF 626414Alternative Names: PF-06260414; PF-0626414; PF-626414
Latest Information Update: 05 Aug 2015
At a glance
- Originator Pfizer
- Mechanism of Action Androgen receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cachexia
Most Recent Events
- 28 Jul 2015 Discontinued - Phase-I for Cachexia in USA (PO)
- 27 Apr 2015 Pfizer terminates a phase I trial (In volunteers) in USA (NCT02393807)
- 26 Mar 2015 Pfizer plans a phase I pharmacokinetic trial for Healthy volunteers in USA (NCT02393807)